Meso Aftermath Archived

辉瑞对礼来和诺和诺德 GLP-1 双寡头的潜在挑战

活动下降——叙事失去相关性。

评分
0.3
动能
▲ 0.0
文章
13
来源
3

热门股

股票代码板块变动
LLY
Healthcare+5.4%
PFE
Healthcare+4.8%
NVO
Healthcare-1.1%
GLP
Energy+0.8%

情绪时间线

板块表现

股票表现

事件时间线

八月 07, 2026
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy … Neutral
八月 05, 2026
Novo Nordisk's raised forecast fails to change the debate over its obesity … Neutral
七月 31, 2026
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings Bearish
七月 28, 2026
Where Will Novo Nordisk Stock Be in 3 Years? Bearish
七月 20, 2026
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss … Neutral
七月 11, 2026
Is Pfizer on Track to Launch Its Next Lipitor -- This Time … Neutral
六月 30, 2026
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock Bullish
六月 24, 2026
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other … Neutral
六月 12, 2026
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors … Bullish
五月 21, 2026
Eli Lilly says next-generation weight loss drug clears crucial obesity trial Bullish
五月 09, 2026
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? Neutral
五月 07, 2026
Pfizer pins post 2028 return to growth on new obesity and cancer … Bullish
四月 21, 2026
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's … Neutral

假设

Pending 到期: 2026年8月19日

Pfizer's GLP-1 candidate will fail to meet primary efficacy endpoints in Phase 3 trials or face manufacturing/supply chain delays, pushing commercial launch beyond Q4 2025.

Pending 到期: 2026年10月18日

LLY stock will outperform PFE stock by at least 12% over the next 6 months despite GLP-1 competition concerns, as Mounjaro's first-mover advantage and pipeline depth maintain investor confidence.

Pending 到期: 2026年10月18日

Pfizer's monthly GLP-1 injection will capture at least 15% market share from Eli Lilly (LLY) and Novo Nordisk (NVO) within 24 months of FDA approval, driven by superior dosing convenience and comparable efficacy data.

相关文章

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock

Nasdaq · 六月 30, 2026
Bearish

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete …

Yahoo Finance · 六月 24, 2026
Mixed

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry …

Nasdaq · 六月 12, 2026
Neutral

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

CNBC · 五月 21, 2026
Mixed

Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?

Nasdaq · 五月 09, 2026
Mixed

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Yahoo Finance · 四月 21, 2026
Mixed

相关叙事

Emerging 1%

Kingdom Capital Advisors' position in KODK

评分: 0.5
Emerging 1%

Kingdom Capital Advisors investment thesis for AENT

评分: 0.5
Emerging 1%

MIRM earnings call transcript

评分: 0.4
🤖

AI概览

辉瑞公司可能挑战礼来和诺和诺德的 GLP-1 双寡头垄断

辉瑞公司已将目光投向了由礼来公司和诺和诺德公司自 2017 年以来一直主导的减肥药市场。礼来和诺和诺德近期都获得了口服 GLP-1 药物的批准，将其产品线从注射剂扩展到口服剂。然而，辉瑞公司预计其减肥药管线将在 2028 年后推动增长，可能打破目前的双寡头垄断格局。

目前价值 100 亿美元的减肥药市场有望实现显著增长。辉瑞公司的进入可能会加剧竞争，给礼来公司和诺和诺德公司的市场份额和估值带来压力。这两家公司的投资者都应密切关注辉瑞公司的临床试验进展和监管批准情况。

即将到来的关键催化剂包括辉瑞公司领先的减肥药 setimiglitude 的第三阶段试验结果，预计将于 2023 年第四季度公布，以及美国 FDA 对该药物批准的决定，预计将于 2024 年第二季度公布。此外，投资者还应关注辉瑞公司的财报电话会议，以获取其减肥药管线和潜在上市时间的最新信息。
AI概览（截至） 八月 05, 2026

时间线

首次发现八月 07, 2026
最后更新八月 21, 2026